Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
September 14, 2021 07:00 ET
|
Galera Therapeutics
Event to be webcast on Thursday, September 23 at 11:00 a.m. ET Phase 3 ROMAN trial of avasopasem manganese, Galera’s lead candidate for SOM in patients with head and neck cancer, expected to read out...
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
September 08, 2021 07:00 ET
|
Galera Therapeutics
Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate Hazard ratios better than 0.5 on all survival and tumor outcome...
Galera to Present at Three Upcoming Investor Conferences in September
September 07, 2021 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments
August 10, 2021 07:00 ET
|
Galera Therapeutics
Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near doubling in median overall...
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
June 28, 2021 07:00 ET
|
Galera Therapeutics
Topline data expected in the second half of 2021 Triggers $37.5M milestone payment from Blackstone Life Sciences MALVERN, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq:...
Galera to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
May 17, 2021 07:00 ET
|
Galera Therapeutics
Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial Triggers $20M milestone payment from Blackstone Life Sciences 160-patient randomized, multicenter,...
Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors
May 12, 2021 16:01 ET
|
Galera Therapeutics
Describes mechanism which sensitizes cancer cells to radiotherapy Supports recent results showing a near doubling of median overall survival observed in patients with pancreatic cancer by combining...
Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments
May 11, 2021 07:00 ET
|
Galera Therapeutics
Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall survival observed in...
Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
May 05, 2021 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...